Lurbinectedin is a novel drug used for the treatment of small cell lung cancer and other solid tumors. Not using Lurbinectedin may result in several drawbacks.

Firstly, Lurbinectedin has shown promising results in the treatment of small cell lung cancer (SCLC), which is a highly aggressive and deadly form of lung cancer [1]. The drug has been found to be effective in treating platinum-resistant SCLC, which is a major clinical challenge [2]. Thus, not using Lurbinectedin may lead to a lack of effective treatment options for SCLC patients.

Secondly, Lurbinectedin has been found to be effective against other types of solid tumors, including ovarian cancer, breast cancer, and Ewing's sarcoma [3]. Thus, not using Lurbinectedin may limit the treatment options available for patients with these types of cancer.

Thirdly, Lurbinectedin has been found to have a manageable safety profile, with most adverse events being mild to moderate in severity [2]. Thus, not using Lurbinectedin may result in patients being exposed to more toxic and less tolerable treatments.

In conclusion, not using Lurbinectedin may result in a lack of effective treatment options for patients with small cell lung cancer and other types of solid tumors. It may also limit the treatment options available and expose patients to more toxic treatments.

Sources:
[1] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8165873/
[2] https://www.sciencedirect.com/science/article/pii/S0169500220306401
[3] https://www.drugpatentwatch.com/p/tradename/LURBINECTEDIN